Abstract: The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease.
Abstract: The present invention describes the identification, isolation, cloning, and sequencing of the Alzheimer Related Membrane Protein (ARMP) gene for both normal and mutant forms. An analogous mouse gene, mARMP gene, has also been isolated, cloned, and sequenced. The gene transcript and gene products are used in developing DNA diagnosis for and detection of carriers of the gene, Alzheimer's Disease diagnosis, gene therapy, protein therapy, immunotherapy, as well as the isolation and manufacture of the protein and the development of transgenic animals carrying mutations in the ARMP gene.
Type:
Grant
Filed:
June 28, 1995
Date of Patent:
April 3, 2001
Assignee:
HSC Research and Development Limited Partnership
Inventors:
Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
Abstract: The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.
Type:
Application
Filed:
June 24, 2002
Publication date:
September 25, 2003
Applicant:
University of Washington
Inventors:
Rudolph E. Tanzi, Gerard D. Schellenberg, Wilma Wasco, Ephrat Levy-Lahad, Thomas D. Bird, David J. Galas
Abstract: Isolated nucleic acid molecules are provided encoding human PS1 gene products. Mutant PS1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of the activity of the PS1 polypeptide and mutants thereof. Also provided are diagnostic methods for detecting Alzheimer's disease and therapeutic methods for treating the same.
Abstract: The present invention relates to a culture of human olfactory neurons. The neurons may display a normal neuronal pathology or a pathology characteristic of a generalized central nervous system disease. The cultured neurons can be used for neurotoxicity tests, screening for therapeutic drugs and anti-viral agents, and diagnosing Alzheimer's disease.
Type:
Grant
Filed:
October 30, 1990
Date of Patent:
February 9, 1999
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A method diagnosing Alzheimer's disease in a patient includes analyzing conformational changes in a band 3 protein of the patient yielding a time course of the conformational changes. One approach includes analyzing conformational changes in a band 3 protein by measuring band 3 Cl.sup.- /HCO.sub.3.sup.- exchange over time. In this approach a double exponential function is solved for two rate constant estimates by fitting the double exponential function to the time course. At least one of the rate constant estimates is used to determine whether the patient has Alzheimer's disease. A second approach includes analyzing conformational changes in a band 3 protein by measuring the emission spectrum of a stilbene bound to band 3, which emission changes in response to band 3 conformational changes. In this approach, a single exponential function is solved for a parameter by fitting the single exponential function to the time course obtained.
Type:
Grant
Filed:
September 16, 1997
Date of Patent:
February 29, 2000
Assignee:
President and Fellows of Harvard College
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
August 29, 2003
Publication date:
August 26, 2004
Inventors:
Mark E. Gurney, Michael J. Bienkowaki, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
November 6, 2003
Publication date:
November 25, 2004
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
February 28, 2001
Publication date:
August 30, 2001
Applicant:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention discloses nucleic acid molecules encoding AD4 gene products, expression vectors and host cells suitable for expressing such gene products. Also disclosed are methods for treating, preventing, and diagnosing Alzheimer's Disease.
Type:
Grant
Filed:
August 16, 1999
Date of Patent:
October 22, 2002
Assignees:
The General Hospital Corp., University of Washington
Inventors:
Rudolph E. Tanzi, Gerard D. Schellenberg, Wilma Wasco, Ephrat Levy-Lahad, Thomas D. Bird, David J. Galas
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
July 11, 2007
Publication date:
July 17, 2008
Applicant:
PHARMACIA & UPJOHN CO.
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: Anti-sense peptides that correspond to Amyloid-&bgr; protein residues 1-43 are identified, and are used to identify protein binding sites on enzymes that interact with Amyloid-&bgr;. The anti-sense peptides can be used as, or to identify, therapeutic agents that prevent Amyloid-&bgr; cytotoxicity, and may be useful in the treatment of Alzheimer's disease. The anti-sense peptides show sequence similarity to the protein kinase cdc2, and it has now been found that the cytotoxic form of A&bgr; is phosphorylated.
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
August 29, 2003
Publication date:
March 4, 2004
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
February 27, 2001
Publication date:
May 30, 2002
Applicant:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunization in the purpose of treating or preventing AD. The invention further relates to a peptide, A&bgr;-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunization against AD.
Type:
Application
Filed:
July 9, 2001
Publication date:
October 31, 2002
Inventors:
Lars Lannfelt, Camilla Nilsberth, Anita Westlind-Danielsson, Jan Naslund
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Application
Filed:
August 29, 2003
Publication date:
March 11, 2004
Inventors:
Mark K. Gurney, Michael J. Bienkowaki, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention relates to the identification, isolation and cloning of a mammalian polynucleotide which encodes a Alzheimer's related membrane protein (ARMP). The invention also contemplates mutant polynucleotides and polynucleotides that encode ARMP homologs. Vectors encoding the protein and host cells transfected with the vector are further contemplated by the present invention.
Type:
Grant
Filed:
April 28, 1995
Date of Patent:
March 11, 2003
Assignees:
The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
Inventors:
Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the ?-secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
March 15, 2005
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
May 9, 2006
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan